Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I study of INC280 in c-MET-dependent advanced solid tumors
NL-OMON43929Phase 1Recruiting
- Sponsor
- Novartis
- Start
- Feb 2012
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of capmatinib in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC), glioblastoma (GBM) and 1 more (2 arms), sponsored by Novartis. Primary endpoints: Dose-limiting toxicity, Safety and tolerability and 4 more. Started Feb 2012; status: recruiting.
02
Drugs
capmatinib
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)glioblastoma (GBM)hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NL-OMON43929.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43929.